154 related articles for article (PubMed ID: 37768447)
1. SOX combined with sintilimab versus SOX alone in the perioperative management of locally advanced gastric cancer: a propensity score-matched analysis.
Huang X; Fang J; Huang L; Chen H; Chen H; Chai T; Ye Z; Chen H; Xu Q; Du Y; Yu P
Gastric Cancer; 2023 Nov; 26(6):1040-1050. PubMed ID: 37768447
[TBL] [Abstract][Full Text] [Related]
2. [Safety and effectiveness of oxaliplatin combined with capecitabine or oxaliplatin combined with S-1 neoadjuvant chemotherapy in the treatment of advanced gastric cancer].
Xie BW; Zang L; Ma JJ; Sun J; Yang X; Wang ML; Lu AG; Hu WG; Zheng MH
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):138-144. PubMed ID: 33508919
[No Abstract] [Full Text] [Related]
3. The protocol of a prospective, multicenter, randomized, controlled phase III study evaluating different cycles of oxaliplatin combined with S-1 (SOX) as neoadjuvant chemotherapy for patients with locally advanced gastric cancer: RESONANCE-II trial.
Wang X; Li S; Sun Y; Li K; Shen X; Xue Y; Liang P; Li G; Chen L; Zhao Q; Li G; Fu W; Liang H; Xin H; Suo J; Fang X; Zheng Z; Xu Z; Chen H; Zhou Y; He Y; Huang H; Zhu L; Yang K; Ji J; Ye Y; Zhang Z; Li F; Wang X; Tian Y; Park S; Chen L
BMC Cancer; 2021 Jan; 21(1):20. PubMed ID: 33402102
[TBL] [Abstract][Full Text] [Related]
4. Combined systemic immune-inflammatory index (SII) and prognostic nutritional index (PNI) predicts chemotherapy response and prognosis in locally advanced gastric cancer patients receiving neoadjuvant chemotherapy with PD-1 antibody sintilimab and XELOX: a prospective study.
Ding P; Guo H; Sun C; Yang P; Kim NH; Tian Y; Liu Y; Liu P; Li Y; Zhao Q
BMC Gastroenterol; 2022 Mar; 22(1):121. PubMed ID: 35287591
[TBL] [Abstract][Full Text] [Related]
5. Short-term curative effect of S-1 plus oxaliplatin as perioperative chemotherapy for locally advanced gastric cancer: a prospective comparison study.
Zhao Q; Li Y; Huang J; Fan L; Tan B; Tian Y; Yang P; Jiao Z; Zhao X; Zhang Z; Wang D; Liu Y
Pharmazie; 2017 Apr; 72(4):236-240. PubMed ID: 29441995
[TBL] [Abstract][Full Text] [Related]
6. [Safety and efficacy of adjuvant chemotherapy with oxaliplatin and S-1 for patients with locally advanced gastric cancer after D2 lymph nodes dissection].
Bao YD; Zhang H; Dong L; Jiang KW; Ye YJ; Wang S; Zhou J
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):145-152. PubMed ID: 33508920
[No Abstract] [Full Text] [Related]
7. [Prognostic analysis of neoadjuvant chemotherapy for locally advanced gastric cancer with propensity score matching method].
Peng L; Yang W; Zhang Z; Zhi C; Zhou X; Liu H; Hua Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Oct; 21(10):1148-1153. PubMed ID: 30370514
[TBL] [Abstract][Full Text] [Related]
8. [A multi-center retrospective study of perioperative chemotherapy for gastric cancer based on real-world data].
Ding XW; Zheng ZC; Zhao Q; Zhai G; Liang H; Wu X; Zhu ZG; Wang HJ; He QS; He XL; Du YA; Chen LC; Hua YW; Huang CM; Xue YW; Zhou Y; Zhou YB; Wu D; Fang XD; Dai YG; Zhang HW; Cao JQ; Li LP; Chai J; Tao KX; Li GL; Jie ZG; Ge J; Xu ZF; Zhang WB; Li QY; Zhao P; Ma ZQ; Yan ZL; Zheng GL; Yan Y; Tang XL; Zhou X
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 May; 24(5):403-412. PubMed ID: 34000769
[No Abstract] [Full Text] [Related]
9. Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial.
Zhang X; Liang H; Li Z; Xue Y; Wang Y; Zhou Z; Yu J; Bu Z; Chen L; Du Y; Wang X; Wu A; Li G; Su X; Xiao G; Cui M; Wu D; Chen L; Wu X; Zhou Y; Zhang L; Dang C; He Y; Zhang Z; Sun Y; Li Y; Chen H; Bai Y; Qi C; Yu P; Zhu G; Suo J; Jia B; Li L; Huang C; Li F; Ye Y; Xu H; Wang X; Yuan Y; E JY; Ying X; Yao C; Shen L; Ji J;
Lancet Oncol; 2021 Aug; 22(8):1081-1092. PubMed ID: 34252374
[TBL] [Abstract][Full Text] [Related]
10. Impact of Programmed Death-Ligand 1 Expression on Mismatch Repair Deficiency and Epstein-Barr Virus Status on Survival Outcomes in Patients with Stage II/III Gastric Cancer After Surgery.
Akimoto E; Kuwata T; Shitara K; Kawazoe A; Sakamoto N; Ishii G; Ochiai A; Kinoshita T
Ann Surg Oncol; 2023 Aug; 30(8):5227-5236. PubMed ID: 36934377
[TBL] [Abstract][Full Text] [Related]
11. mFOLFOXIRI versus mFOLFOX6 as neoadjuvant chemotherapy in locally advanced rectal cancer: A Propensity Score Matching Analysis.
Ding M; Zhang J; Hu H; Cai Y; Ling J; Wu Z; Xie X; Li J; Li W; Deng Y
Clin Colorectal Cancer; 2022 Mar; 21(1):e12-e20. PubMed ID: 34963563
[TBL] [Abstract][Full Text] [Related]
12. The efficacy and safety of neoadjuvant chemotherapy on patients with advanced gastric cancer: A multicenter randomized clinical trial.
Zhao Q; Lian C; Huo Z; Li M; Liu Y; Fan L; Tan B; Zhao X; Zhang Z; Wang D; Liu Y; Guo H; Yang P; Tian Y; Li Y
Cancer Med; 2020 Aug; 9(16):5731-5745. PubMed ID: 32583567
[TBL] [Abstract][Full Text] [Related]
13. [Safety and efficacy of laparoscopic surgery in locally advanced gastric cancer patients with neoadjuvant chemotherapy combined with immunotherapy].
Lv JB; Yin YP; Zhang P; Cai M; Chen JH; Li W; Li G; Wang Z; Wang GB; Tao KX
Zhonghua Wei Chang Wai Ke Za Zhi; 2023 Jan; 26(1):84-92. PubMed ID: 36650004
[No Abstract] [Full Text] [Related]
14. Effect of S-1 Plus Oxaliplatin Compared With Fluorouracil, Leucovorin Plus Oxaliplatin as Perioperative Chemotherapy for Locally Advanced, Resectable Gastric Cancer: A Randomized Clinical Trial.
Yu J; Gao Y; Chen L; Wu D; Shen Q; Zhao Z; Liu W; Yang H; Zhang Q; Wang X; Hu P; Zheng Z; Wang X; Liu H; Xu Z; Yan Z; Wu Y; Jin M; Zhang Q; Liu X; Zhu K; Shou C
JAMA Netw Open; 2022 Feb; 5(2):e220426. PubMed ID: 35226081
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of camrelizumab plus chemotherapy versus chemotherapy alone in patients with untreated, HER2-negative, unresectable locally advanced, or metastatic gastric cancer or gastroesophageal junction cancer: a retrospective comparative cohort study.
Xiang J; Gong W; Sun P; Wang X; Liu A
J Gastrointest Oncol; 2022 Dec; 13(6):2874-2884. PubMed ID: 36636085
[TBL] [Abstract][Full Text] [Related]
16. [Short-term outcome of programmed cell death protein1 (PD-1) antibody combined with total neoadjuvant chemoradiotherapy in the treatment of locally advanced middle-low rectal cancer with high risk factors].
Li YJ; Zhang L; Dong QS; Cai Y; Zhang YZ; Wang L; Yao YF; Zhang XY; Li ZW; Li YH; Sun YS; Wang WH; Wu AW
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Nov; 24(11):998-1007. PubMed ID: 34823301
[No Abstract] [Full Text] [Related]
17. Clinical evaluation of cetuximab combined with an S-1 and oxaliplatin regimen for Chinese patients with advanced gastric cancer.
Zhang ZD; Kong Y; Yang W; Zhang B; Zhang YL; Ma EM; Liu HX; Chen XB; Hua YW
World J Surg Oncol; 2014 Apr; 12():115. PubMed ID: 24758484
[TBL] [Abstract][Full Text] [Related]
18. The validity of neoadjuvant chemotherapy with paclitaxel plus S-1 is not inferior to that of SOX regimen for locally advanced gastric cancer: an observational study.
Zhang C; Wu B; Yang H; Yao Z; Zhang N; Tan F; Liu M; Xu K; Chen L; Xing J; Cui M; Su X
BMC Cancer; 2022 Nov; 22(1):1223. PubMed ID: 36443694
[TBL] [Abstract][Full Text] [Related]
19. The effect of perioperative chemotherapy for patients with an adenocarcinoma of the gastroesophageal junction: A propensity score matched analysis.
Parry K; van Rossum PS; Haj Mohammad N; Ruurda JP; van Hillegersberg R
Eur J Surg Oncol; 2017 Jan; 43(1):226-233. PubMed ID: 27424786
[TBL] [Abstract][Full Text] [Related]
20. [Comparison of the efficacy and safety of capecitabine or tegafur, gimeracil and oteracil potassium capsules combined with oxaliplatin chemotherapy regimens in the treatment of advanced gastric cancer].
Wan Y; Hui H; Wang X; Wu J; Sun S
Zhonghua Zhong Liu Za Zhi; 2016 Jan; 38(1):28-34. PubMed ID: 26796803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
